Moberg Pharma AB (publ) (STO:MOB)

Market Cap	478.94M +25.5%
Revenue (ttm)	13.54M +38.0%
Net Income	-27.24M
EPS	-0.58
Shares Out	47.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,445
Average Volume	79,381
Open	10.15
Previous Close	10.35
Day's Range	9.47 - 10.43
52-Week Range	6.52 - 12.10
Beta	1.15
RSI	65.00
Earnings Date	Feb 17, 2026

About Moberg Pharma AB

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MOB

Financial Performance

In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.